Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire

NEW YORK, March 24, 2025

Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase

Recognized EsoGuard revenue of $1.2 million in 4Q24

New sales channel generated over 20 new cash-pay concierge medicine contracts

Secured first agreement to pay for EsoGuard under state biomarker legislation

Conference call and webcast to be held today, March 24(th) at 8:30 AM EDT

NEW YORK, March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024.

Conference Call and Webcast

The webcast will take place on Monday, March 24, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

Business Highlights

"The Lucid team finished 2024 on a strong note and 2025--which promises to be a pivotal year--is off to an exceptional start marked by significant advancements in EsoGuard's commercial coverage, sales channels, and clinical evidence base," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We believe we are on the cusp of achieving broader payor coverage for EsoGuard and expect our focus on new contractually-guaranteed revenue sales channels, including concierge medicine, to drive revenue growth in the second half of 2025. We are now well positioned to capitalize on EsoGuard's very large clinical and market opportunity."

   -- Recognized $1.2 million in EsoGuard revenue for 4Q24. 
 
   -- Processed a single-quarter record of 4,042 EsoGuard tests in 4Q24, a 45% 
      sequential increase and 84% annual increase. 
 
   -- Executed over 20 cash-pay concierge medicine contracts in the first few 
      weeks following the launch of new sales channels targeting 
      contractually-guaranteed revenue. 
 
   -- Secured first positive commercial insurance coverage policy for EsoGuard 
      from Highmark Blue Cross Blue Shield, establishing a strong precedent to 
      drive additional positive policy coverage decisions. 
 
   -- Secured first agreement to pay for EsoGuard under state biomarker 
      legislation with Blue Cross Blue Shield of Rhode Island. 
 
   -- Submitted EsoGuard clinical evidence package to MolDX in support of a 
      request for reconsideration of existing Medicare Local Coverage 
      Determination $(LCD.AU)$. 
 
   -- Updated National Comprehensive Cancer Network$(R)$ (NCCN) Clinical Practice 
      Guidelines now includes a section on esophageal precancer screening which 
      references existing professional society guidelines recommending 
      non-endoscopic biomarker testing, such as EsoGuard, as an acceptable 
      alternative to invasive upper endoscopy to detect esophageal precancer. 
 
   -- CLUE and ENVET-BE clinical utility studies accepted for peer-reviewed 
      publication, further strengthening EsoGuard's already robust clinical 
      evidence package. CLUE, now published, demonstrated high patient 
      compliance with referral to endoscopy following a positive EsoGuard 
      result. ENVET-BE demonstrated a nearly three-fold increase in the 
      positive diagnostic yield of invasive endoscopy in at-risk patients 
      recommended for precancer testing by ACG guidelines, further solidifying 
      EsoGuard's role as a non-invasive triage tool. 
 
   -- Case Western Reserve University and University Hospitals investigators 
      awarded $8 million NIH grant to study EsoGuard for expanded indication in 
      patients without GERD, potentially increasing the total addressable 
      market opportunity beyond the current $60 billion based on an estimated 
      30 million at-risk patients with chronic GERD. 
 
   -- Completed a $22 million convertible debt refinancing and a $15.3 million 
      common stock financing, yielding a total of $32.8 million in net proceeds 
      which extended cash runway beyond key reimbursement milestones. 
      Eliminated "baby shelf" restrictions, providing greater flexibility for 
      future financings. 
 
   -- Regained compliance with Nasdaq minimum bid price requirement for 
      continued listing on the Nasdaq Capital Market. 

Financial Results

   -- For the three months ended December 31, 2024, EsoGuard related revenues 
      were $1.2 million. Operating expenses were approximately $13.6 million, 
      which included stock-based compensation expenses of $1.2 million. GAAP 
      net loss attributable to common stockholders was approximately $11.5 
      million or $(0.20) per common share. 
 
   -- As shown below and for the purpose of illustrating the effect of 
      stock-based compensation and other non-cash income and expenses on the 
      Company's financial results, the Company's non-GAAP adjusted loss for the 
      three months ended December 31, 2024, was approximately $10.9 million or 
      $(0.19) per common share. 
 
   -- Lucid had cash and cash equivalents of $22.4 million as of December 31, 
      2024. Pro forma cash, including the first quarter 2025 common stock 
      financing, is approximately $36.9 million at the start of 2025. 
 
   -- The audited financial results for the year ended December 31, 2024, were 
      filed with the SEC on Form 10-K on March 24, 2025, and available at 
      www.luciddx.com or www.sec.gov. 

Lucid Non-GAAP Measures

   -- To supplement our unaudited financial results presented in accordance 
      with U.S. generally accepted accounting principles (GAAP), management 
      provides certain non-GAAP financial measures of the Company's financial 
      results. These non-GAAP financial measures include net loss before 
      interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP 
      adjusted loss, which further adjusts EBITDA for stock-based compensation 
      expense and other non-cash income and expenses, if any. The foregoing 
      non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not 
      recognized terms under U.S. GAAP. 
 
   -- Non-GAAP financial measures are presented with the intent of providing 
      greater transparency to the information used by us in our financial 
      performance analysis and operational decision-making. We believe these 
      non-GAAP financial measures provide meaningful information to assist 
      investors, shareholders, and other readers of our unaudited financial 
      statements in making comparisons to our historical financial results and 
      analyzing the underlying performance of our results of operations. These 
      non-GAAP financial measures are not intended to be, and should not be, a 
      substitute for, considered superior to, considered separately from, or as 
      an alternative to, the most directly comparable GAAP financial measures. 
 
   -- Non-GAAP financial measures are provided to enhance readers' overall 
      understanding of our current financial results and to provide further 
      information for comparative purposes. Management believes the non-GAAP 
      financial measures provide useful information to management and investors 
      by isolating certain expenses, gains, and losses that may not be 
      indicative of our core operating results and business outlook. 
      Specifically, the non-GAAP financial measures include non-GAAP adjusted 
      loss, and its presentation is intended to help the reader understand the 
      effect of the loss on the issuance or modification of convertible 
      securities, the periodic change in fair value of convertible securities, 
      the loss on debt extinguishment, and the corresponding accounting for 
      non-cash charges on financial performance. In addition, management 
      believes non-GAAP financial measures enhance the comparability of results 
      against prior periods. 
 
   -- A reconciliation to the most directly comparable GAAP measure of all 
      non-GAAP financial measures included in this press release for the three 
      months and years ended December 31, 2024, and 2023 are as follows: 
 
Condensed consolidated statements of operations (unaudited) 
  (in thousands 
except per-share           For the three months ended                    For the year ended 
    amounts)                      December 31,                              December 31, 
                           2024                 2023                 2024                 2023 
                    -------------------  -------------------  -------------------  ------------------- 
 
Revenue              $            1,197   $            1,040   $            4,346   $            2,428 
 
Operating expenses               13,571               12,494               50,398               50,910 
Other (Income) 
 expense                          (833)                (625)                (523)                4,184 
                    -------------------  -------------------  -------------------  ------------------- 
 Net Loss                      (11,541)             (10,829)             (45,529)             (52,666) 
                    -------------------  -------------------  -------------------  ------------------- 
 Net income (loss) 
  per common 
  share, basic and 
  diluted           $            (0.20)  $            (0.26)  $            (1.05)  $            (1.26) 
Net loss 

 attributable to 
 common 
 stockholders                  (11,541)             (10,829)             (53,025)             (52,666) 
Preferred Stock 
dividends and 
deemed dividends                     --                   --                7,496                   -- 
                    -------------------  -------------------  -------------------  ------------------- 
 Net income (loss) 
  as reported                  (11,541)             (10,829)             (45,529)             (52,666) 
                    -------------------  -------------------  -------------------  ------------------- 
Adjustments: 
 Depreciation and 
  amortization 
  expense(1)                        222                  629                1,167                2,499 
 Interest expense, 
  net(2)                           (58)                 (85)                (296)                  (8) 
                    -------------------  -------------------  -------------------  ------------------- 
EBITDA                         (11,377)             (10,285)             (44,658)             (50,175) 
 
Other non-cash or 
financing related 
expenses: 
 Stock-based 
  compensation 
  expense(3)                      1,172                  965                4,534                6,822 
 ResearchDx 
  acquisition paid 
  in stock(1)                        --                   --                   --                  713 
 Operating 
  expenses issued 
  in stock(1)                        98                   --                  346                   23 
 Change in FV 
  convertible 
  debt(2)                       (4,825)                $(540.SI)$              (5,394)                2,980 
 Offering costs 
  convertible 
  debt(2)                            --                   --                   --                1,186 
 Debt 
  extinguishments 
  loss - Senior 
  Secured 
  Convertible 
  Note(2)                         4,050                   --                5,167                   26 
                    -------------------  -------------------  -------------------  ------------------- 
Non-GAAP adjusted 
 (loss)               $        (10,882)   $          (9,860)    $        (40,005)    $        (38,425) 
                    ===================  ===================  ===================  =================== 
 Basic and Diluted 
  shares 
  outstanding                    58,378               42,330               50,516               41,756 
 Non-GAAP adjusted 
  (loss) income 
  per share                     $(0.19)              $(0.23)              $(0.79)              $(0.92) 
 
 
 
(1) Included in general and administrative expenses in the financial 
statements. 
(2) Included in other income and expenses. 
(3) Stock-based compensation ("SBC") expense included in operating expenses is 
detailed as follows in the table below by category within operating expenses 
for the non-GAAP Net operating expenses: 
 
 
Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses 
 (in thousands 
except per-share         For the three months ended                  For the year ended 
    amounts)                    December 31,                            December 31, 
                          2024                2023                2024                2023 
                   ------------------  ------------------  ------------------  ------------------ 
Cost of revenues   $            2,145  $            1,458  $            7,099  $            5,979 
 Stock-based 
  compensation 
  expense(3)                     (42)                (30)               (164)               (100) 
                   ------------------  ------------------  ------------------  ------------------ 
 Net cost of 
  revenues                      2,103               1,428               6,935               5,879 
                   ==================  ==================  ==================  ================== 
 
Amortization of 
 intangible 
 assets                           105                 505                 686               2,021 
 
Sales and 
 marketing                      4,003               4,408              16,463              16,404 
 Stock-based 
  compensation 
  expense(3)                    (300)               (356)             (1,365)             (1,411) 
                   ------------------  ------------------  ------------------  ------------------ 
 Net sales and 
  marketing                     3,703               4,052              15,098              14,993 
                   ==================  ==================  ==================  ================== 
 
General and 
 administrative                 5,865               4,205              20,158              19,254 
 Depreciation 
  expense                       (117)               (124)               (481)               (478) 
 RDx Settlement 
  in Stock                         --                  --                  --               (713) 
 Operating 
  expenses issued 
  in stock                       (98)                  --               (346)                (23) 
 Stock-based 
  compensation 
  expense(3)                    (691)               (390)             (2,330)             (4,628) 
                   ------------------  ------------------  ------------------  ------------------ 
 Net general and 
  administrative                4,959               3,691              17,001              13,412 
                   ==================  ==================  ==================  ================== 
 
Research and 
 development                    1,453               1,918               5,992               7,252 
 Stock-based 
  compensation 
  expense(3)                    (139)               (189)               (675)               (683) 
                   ------------------  ------------------  ------------------  ------------------ 
 Net research and 
  development                   1,314               1,729               5,317               6,569 
                   ==================  ==================  ==================  ================== 
 
Total operating 
 expenses                      13,571              12,494              50,398              50,910 
 Depreciation and 
  amortization 
  expense                       (222)               (629)             (1,167)             (2,499) 
 RDx Settlement 
  in Stock                         --                  --                  --               (713) 
 Operating 
  expenses issued 
  in stock                       (98)                  --               (346)                (23) 
 Stock-based 
  compensation 
  expense(3)                  (1,172)               (965)             (4,534)             (6,822) 
                   ------------------  ------------------  ------------------  ------------------ 
 Net operating 
  expenses          $          12,079   $          10,900   $          44,351   $          40,853 
                   ==================  ==================  ==================  ================== 
 

About EsoGuard and EsoCheck

Millions of patients with gastroesophageal reflux disease (GERD) are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer ("EAC"). Over 80 percent of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S. The mortality rate is high even in those diagnosed with early stage EAC. The U.S. incidence of EAC has increased 500 percent over the past four decades, while the incidences of other common cancers have declined or remained flat. In nearly all cases, EAC silently progresses until it manifests itself with new symptoms of advanced disease. All EAC is believed to arise from esophageal precancer, which occurs in approximately 5 percent to 15 percent of at-risk GERD patients. Early esophageal precancer can be monitored for progression to late esophageal precancer which can be cured with endoscopic esophageal ablation, reliably halting progression to cancer.

Esophageal precancer screening is already recommended by clinical practice guidelines for the millions of GERD patients with multiple risk factors, including age over 50 years, male sex, White race, obesity, smoking history, and a family history of esophageal precancer or cancer. Unfortunately, fewer than 10 percent of those recommended for screening undergo traditional invasive endoscopic screening. The profound tragedy of an EAC diagnosis is that death could likely have been prevented if the at-risk GERD patient had been screened and then undergone surveillance and curative treatment at the precancer stage.

The only missing element for a viable esophageal cancer prevention program has been the lack of an easily-accessible, in-office screening tool that can detect esophageal precancer. Lucid believes EsoGuard, performed on samples collected non-endoscopically with EsoCheck, is the missing element -- the first and only commercially available test capable of serving as a widespread screening tool to prevent esophageal cancer deaths through the early detection of esophageal precancer in at-risk GERD patients. An updated American College of Gastroenterology $(ACG.UK)$ clinical practice guideline and an American Gastroenterological Association (AGA) clinical practice update both endorse non-endoscopic biomarker tests as an acceptable alternative to costly and invasive endoscopy for esophageal precancer screening. EsoGuard is the only such test currently available in the United States.

EsoGuard is a Next Generation Sequencing $(NGS)$ based DNA methylation assay performed on surface esophageal cells collected with EsoCheck, which quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1). The assay was initially evaluated in a 408-patient, multicenter, case-control study published in Science Translational Medicine and showed greater than 90 percent sensitivity and specificity at detecting esophageal precancer and cancer.

EsoCheck is a CE Marked and FDA 510(k) cleared noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in a less than three-minute office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to gently swab surface esophageal cells. When vacuum suction is applied, the balloon and sampled cells are pulled into the capsule, protecting them from contamination and dilution by cells outside of the targeted region during device withdrawal. Lucid believes this proprietary Collect+Protect$(TM)$ technology makes EsoCheck the only noninvasive esophageal cell collection device capable of such anatomically targeted and protected sampling. The sample is sent by overnight express mail to Lucid's CLIA-certified, CAP-accredited, NYS CLEP approved laboratory, LucidDx Labs, for EsoGuard testing.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard(R) Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck(R) Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-results-302409164.html

SOURCE Lucid Diagnostics

/CONTACT: Investor and Media Contact: Matt Riley, PAVmed and Lucid Diagnostics, mjr@pavmed.com

(END) Dow Jones Newswires

March 24, 2025 08:01 ET (12:01 GMT)